Critique Pembrolizumab (Keytruda): CADTH Reimbursement Suggestion: Indicator: In combination with chemotherapy, with the remedy of adult clients with domestically recurrent unresectable or metastatic triple-negative breast cancer which have not acquired prior chemotherapy for metastatic sickness and whose tumours Convey programmed mobile Loss of li